Edgewood Oncology Reports Promising Preclinical Efficacy Data for BTX-A51 in Investigator-Sponsored Liposarcoma Study

Edgewood Oncology Unveils Compelling Preclinical Data Supporting BTX-A51 in Liposarcoma at AACR Annual Meeting 2025 Edgewood Oncology, a clinical-stage biotechnology company dedicated to advancing targeted cancer therapies, today announced new preclinical efficacy data for BTX-A51 in liposarcoma (LPS). The data,…

Read MoreEdgewood Oncology Reports Promising Preclinical Efficacy Data for BTX-A51 in Investigator-Sponsored Liposarcoma Study

Mythic Therapeutics Presents Promising Preclinical Results for MYTX-011 Targeting Diverse Tumor Mutations at AACR 2025

Mythic Therapeutics Presents Promising Preclinical Data Demonstrating Broad Antitumor Efficacy of MYTX-011 at the 2025 AACR Annual Meeting Mythic Therapeutics, a clinical-stage biotechnology company pioneering the next generation of antibody-drug conjugates (ADCs), today unveiled compelling preclinical data supporting the broad…

Read MoreMythic Therapeutics Presents Promising Preclinical Results for MYTX-011 Targeting Diverse Tumor Mutations at AACR 2025

Puma Biotechnology Showcases Neratinib Clinical Findings at AACR Annual Meeting 2025

Puma Biotechnology Showcases Promising Neratinib Combination Data at AACR Annual Meeting 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company specializing in the development of innovative cancer treatments, has presented new clinical data on its lead drug candidate, neratinib (NERLYNX®),…

Read MorePuma Biotechnology Showcases Neratinib Clinical Findings at AACR Annual Meeting 2025

Agenus Unveils Promising BOT/BAL Neoadjuvant Pan-Cancer Findings from NEOASIS Study at AACR

Agenus Presents Promising BOT/BAL Neoadjuvant Pan-Cancer Data from NEOASIS Study at AACR Annual Meeting Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing therapies designed to activate the body’s immune system to fight cancer, announced the presentation of…

Read MoreAgenus Unveils Promising BOT/BAL Neoadjuvant Pan-Cancer Findings from NEOASIS Study at AACR

LEAP Drives Growth in Digital Lab Transformation with New Clinical Diagnostics Executive

LEAP Consulting Group Accelerates Clinical Lab Digital Transformation with Appointment of Dr. Heather E. Williams as Practice Principal, Life Sciences LEAP Consulting Group, a boutique digital consultancy recognized for its domain expertise in the clinical diagnostics space, has announced a…

Read MoreLEAP Drives Growth in Digital Lab Transformation with New Clinical Diagnostics Executive

Fellow Health to Unveil Cutting-Edge Prostate Cancer and PVSA Findings at AUA 2025

Fellow Health to Present Groundbreaking Research on Prostate Cancer Biomarkers and Mail-In PVSA Testing at AUA 2025 Fellow Health, a pioneering healthcare company dedicated to advancing male reproductive health through innovative, patient-centered diagnostics, today announced that it will present four…

Read MoreFellow Health to Unveil Cutting-Edge Prostate Cancer and PVSA Findings at AUA 2025

Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development

Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development, Signaling Strategic Growth in Clinical Pipeline Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company advancing novel treatments for serious central nervous system (CNS) and immunologic…

Read MoreContineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development

Dyno Therapeutics to Unveil Pioneering AAV Gene Delivery Data Targeting CNS, Eye, and Muscle at ASGCT 28th Annual Meeting

Dyno Therapeutics to Present Cutting-Edge AAV Gene Delivery Data for CNS, Eye, and Muscle at 2025 ASGCT Annual Meeting Dyno Therapeutics, Inc., a pioneer in genetic technologies harnessing the power of artificial intelligence (AI) to revolutionize in vivo gene delivery,…

Read MoreDyno Therapeutics to Unveil Pioneering AAV Gene Delivery Data Targeting CNS, Eye, and Muscle at ASGCT 28th Annual Meeting